Prevention and therapy of acne-like rash in cancer patients receiving therapy with EGFR receptor inhibitors
https://doi.org/10.33667/2078-5631-2020-24-42-46
Abstract
Cancer chemotherapy advanced dramatically. The success in the management of a broad spectrum of malignancies was achieved due to the development of targeted chemotherapeutic drugs, such as inhibitors of the epidermal growth factor receptor (iEGFR). The most common dermatologic side effect of iEGFR therapy is an acneiform rash that occurs in 60–80 % of patients. This adverse event develops during the first 2 weeks of treatment with iEGFR. Diagnostics of acneiform rash may be complicated because of different interpretations by oncologists and dermatologists. Acneiform rash is frequently associated with pain and itch. Skin toxicity affects a patient’s quality of life, including physical and psychological well-being, emotional and social adaptation, may lead to dose reduction and iEGFR discontinuation. The degree of acneiform rash correlates with an iEGFR effectiveness, which is currently confirmed by different data. Thus, the prevention and prompt management of dermatologic adverse events is a pressing issue because they influence the anti-cancer treatment prognosis. This article reviews the current recommendations on the prevention and management of iEGFR associated acneiform rash. The authors present their own clinical case of a patient with acneiform rash during panitumumab (monoclonal antibody against EGFR) therapy.
About the Authors
L. S. Kruglova
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation
Moscow
Russian Federation
Moscow
I. A. Korolyova
Samara Medical University ‘REAVIZ’
Russian Federation
Samara
Russian Federation
Samara
E. A. Shatokhina
Central State Medical Academy of the Administrative Department of the President of Russia
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Lacouture ME Anadkat MJ Bensadoun RJ et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support. Care Cancer. 2011. 19 (8), 1079–1095.
2. Burtness B, Anadkat M, Basti S et al. NCCN Task Force report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J. Natl Compr. Cancer Netw. 2009. 7 (Suppl. 1), S5–S21; quiz S22–S24.
3. Королева И. А., Болотина Л. В., Гладков О. А., Горбунова В. А., Круглова Л. С., Манзюк Л. В. и соавт. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию. Злокачественные опухоли: Практические рекомендации RUSSCO, 2018 (том 8). С. 564–574.
4. Hofheinz RD, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Crit Rev Oncol Hematol. 2017; 114: 102–13.
5. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005. 23 (22): 5235–5246.
6. Perez-Soler R, Delord JP, Halpern A et al. HER1/ EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. The Oncologist. 2005. 10 (5): 345–356.
7. Boone SL, Rademaker A, Liu D et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology. 2007. 72 (3–4): 152–159.
8. Segaert S, Chiritescu G, Lemmens L et al. Skin toxicities of targeted therapies. 2009. Eur J Cancer 45 (Suppl 1): 295–308.
9. Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. Clin Oncol. 2005; 23: 5235–46.
10. Balagula Y, et al. Int J Dermatol 2011; 50: 129–46. Wagner LI, Lacouture ME. Oncology (Williston Park) 2007; 21 (Suppl 5): 34–6.
11. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25 (13): 1658–1664.
12. Kobayashi Y., Komatsu Y., Yuki S. et al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol 2015; 11: 617–27.
13. Mitchell EP, et al. STEPP trial: best overall response and PFS in WT KRAS exon 2 subgroup. J Clin Oncol 2009; 27 (Suppl 18): abstract CRA4027 (and poster).
14. Шатохина Е.А., Круглова Л.С. Акнеподобная сыпь – кожная токсическая реакция на применение ингибиторов EGFR // Опухоли головы и шеи. 2018. Т. 8, № 4. С. 48–55.
15. Шатохина Е.А., Круглова Л.С., Полонская А.С., Носикова П. Г. Акнеподобная сыпь – дерматологическое нежелательное явление терапии моноклональными антителами к EGFR // Фарматека. 2020. Т. 27. № 8. С. 56–60.
Review
For citations:
Kruglova L.S., Korolyova I.A., Shatokhina E.A. Prevention and therapy of acne-like rash in cancer patients receiving therapy with EGFR receptor inhibitors. Medical alphabet. 2020;(24):42-46. (In Russ.) https://doi.org/10.33667/2078-5631-2020-24-42-46
Views:
713
Email this article 